Abstract
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma (HL). It shows different histoarchitectural patterns which are reported to be of prognostic significance. This study aimed to investigate the clinicopathological features of NLPHL cases in Shiraz, Iran, and their possible impact on prognosis. Between March 2014 and November 2019, all records for lymphoma were extracted from the electronic files of hospitals affiliated with Shiraz University of Medical Sciences. The slides of all NLPHL cases were extracted and reviewed. Other necessary data was retrieved from hospital records and through direct contact with patients. Among1168 lymphoma cases, 382 were HLs and 19.1% (73) of them were of the NLPHL type. The median age of NLPHL patients was 34 years. Of the patients, 51.5% showed variant patterns, and 11% of them had BM involvement. The variant morphology was significantly associated with BM involvement (p = 0.02). Patients with higher stage tumors had lower OS and PFS rates. Stage, BM involvement, and infra-diaphragmatic involvement were significantly associated with outcomes. The rate of NLPHL and variant morphology seems to be high in our center in Iran. The variant morphology was associated with a higher BM involvement rate but not with OS or PFS. Higher stage, BM, and subdiaphragmatic disease involvement were associated with worse outcomes.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Hodgkin lymphoma (HL) accounts for 15–25% of malignant lymphomas [1, 2]. About 5% of HL cases are reportedly of the nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) type [2,3,4]. Unlike the classic subtypes of HL, NLPHL lacks the classical Hodgkin Reed-Sternberg cells (HRS). Instead of HRS, NLPHL is characterized by a characteristic kind of neoplastic cell called lymphocyte-predominant (LP) cells. These cells do not express CD15 or CD 30, but they do express B cell markers, including CD20 [3]. Epidemiologic, morphologic, and immunophenotypic features of NLPHL are summarized in Table 1.
NLPHL affects mostly males in their 4th decade of life and follows a favorable prognosis in most cases. It is generally a localized disease with an indolent clinical course; however, some cases present with advanced disease characterized by marrow and spleen involvement as well as B symptoms [3]. NLPHL shows variable histoarchitectural growth patterns. Fan et al. in 2003 reported six morphologic patterns in NLPHL patients (Table 2) [6]. It has been reported that there are correlations between growth patterns and the clinical course of the disease [7,8,9,10].
To the best of our knowledge, there is no report from Iran addressing the histoarchitectural or other clinicopathological aspects of NLPHL or their prognostic effects. The current study aimed to find the relative prevalence of NLPHL, the frequency of its different morphologic growth patterns, and the effects of its clinicopathological features on survival and prognosis at hospitals affiliated with Shiraz University of Medical Sciences, Shiraz, Iran. Shiraz University of Medical Sciences is regarded as a referral center in southern Iran.
Materials and methods
Patients and clinical data
The current study was conducted at the Hematopathology Center of Shiraz University of Medical Sciences, Shiraz, Iran. Between March 2014 and March 2019, all records for lymphoma were extracted from the electronic files of hospitals affiliated with Shiraz University of Medical Sciences. The relative prevalence of NLPHL between Hodgkin lymphomas and other types of lymphomas was calculated. Other data including age, gender, primary location of the tumor, stage, BM involvement, treatment information, recurrence, and survival were retrieved from hospital records and through direct contact with patients when needed. The study protocol was approved by the Research Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.MED.REC.1398.466).
Morphology and immunohistochemistry review
The immunohistochemistry (IHC) and hematoxylin and eosin (H&E) slides of all NLPHL cases were extracted from the pathology archives. To confirm the diagnosis of NLPHL CD20, CD30, CD15, CD3, and PD1 slides were reviewed. In some cases, CD57, PAX5, OCT2, BOB1, CD23, and LMP1 stains were also available. LP cells were positive for CD20 and negative for CD15, and CD30. PAX5, OCT2, and BOB1 were helpful in some difficult cases. Rosetting T cells were positive for CD3 and PD1. In challenging cases, CD57, CD4, and CD8 staining were also available [3, 5].The cases were subtyped morphologically based on CD20 and/or PAX5, CD3, PD1, and/or CD57stained slides into six patterns (A to F), according to Fan’s categorization (Table 2) [5, 6]. In cases exhibiting a minor pattern, if the minor and major patterns were in the same category (both were in typical or variant categories), the case was subtyped according to the major pattern. If there was a minor or major component of variant pattern while the other pattern was typical, according to Hartmann et al. [7], these cases were classified based on their variant pattern. Then they were reclassified as classic (patterns A and B) and variant (patterns C to F) types. To differentiate NLPHL from T cell/histiocyte-rich large B cell lymphoma, immunostaining for PD1, CD20, CD3, CD4, and CD8 was used. If there was at least one small B cell nodule containing LP cells, the case was diagnosed as NLPHL. This criterion was present in all cases with D or E patterns. In addition, the presence of PD1-positive T cell rosettes surrounding LP cells was regarded in favor of NLPHL. Dominance of CD8-positive T cells at the stroma was also considered in favor of T cell/histiocyte-rich large B cell lymphoma [5].
Statistical analysis
Fisher’s exact and chi-square tests were used to check the relationship between category variables. The Mann-Whitney U test was used to examine the differences in mean ages with variables in the two groups. The Shapiro-Wilk test was employed to assess normality, and Levene’s test was used for homogeneity of variances. Univariate analysis was conducted by univariate Cox regression for the influence of age, gender, stage, BM involvement, pattern, and subdiaphragmatic involvement on overall survival (OS) and progression-free survival (PFS) times. Variables with significant or borderline significant values (p ≤ .10) in the univariate analysis were entered the Cox model for multiple analyses. All analyses were performed using the SPSS statistical software, version 22. p values less than 0.05 were considered statistically significant.
Results
Between March 2014 and November 2019, 1168 cases of lymphoma were diagnosed in hospitals affiliated with Shiraz University of Medical Sciences, Shiraz, Iran. Among these cases, 382 (32.7%) were Hodgkin lymphomas. NLPHL accounted for 19.1% (n = 73) of the Hodgkin lymphomas. The median age of 73 NLPHL patients was 34 years (ranging between 3 and 74) with a mean of 36.33 ± 14.59 years. There was no significant difference in age between male and female subjects (35.35 ± 13.19 vs. 38.59 ± 16.15, respectively, p = 0.39). The majority of patients were male (69.9%). Eight cases (11%) showed BM involvement, and in 3 of these cases, BM was the primary site of disease presentation (Fig. 1). The median follow-up time was 25 (ranging between 1 and 62) months. At 5 years, the estimation of overall survival was 85%. All cases displayed morphologic and immunophenotypic features characteristic of NLPHL, confirming the original diagnosis. After slide review, 7 cases were excluded from further analysis because of incomplete data, most notably due to small sample size which was not enough to be classified in a morphological pattern subtype. In the remaining cases, 3 (4.7%) of non-BM samples were core needle biopsies and the other non-BM samples (n = 61, 95.3%) were excisional biopsies.
Clinical and demographic characteristics of patients are summarized in Table 3. Sixty percent of tumors were located primarily in the cervical and axillary lymph nodes. There were 5 cases with extranodal primary sites. Two of them were located in the bone marrow, and the others were located in the thigh, submandibular, and retroperitoneal soft tissues. Most patients (66.7%) received chemotherapy plus radiotherapy as primary treatment (Table 3). Different chemotherapy regimens (ABVD, CHOP, or CVP) were used, generally including rituximab. Three patients needed salvage therapy who received chemotherapy based (ICE or DHAP) regimens. Pattern A of Fan et al.’s classification was the most frequent pattern (40.9%). Variant morphology was identified in 51.5% of patients. Seventeen cases showed a minor pattern as well. In 13 of them, the minor and major patterns were in the same category (both were in typical or variant categories). These cases were subtyped according to the major pattern. In 4 of them, there was a minor or major component of variant pattern, while the other pattern was typical. These cases were classified based on their variant pattern. Pattern A was the most common pattern identified in cervical lymph nodes, while in axillary lymph nodes pattern C was more common (Table 4). Sequential biopsies were available in 3 patients. One of them showed diffuse large B cell lymphoma (DLBCL) in the relapsed sample.
Figures 2 and 3 demonstrate findings in NLPHL with “typical (Pattern A)” and “variant (Pattern C)” morphologies.
The relationship between histoarchitectural patterns (typical versus variant) and other demographic and clinical characteristics of patients are shown in Table 5. There was a significant association between BM involvement and histoarchitectural pattern (p = 0.025). All patients with BM involvement exhibited variant morphology. Two (33%) of them showed pattern C and 4 (66.6%) exhibited pattern E. Patients with BM involvement had a younger age than those who did not (26.33 ± 20.94 vs. 37.58 ± 14.37, respectively, p = 0.05).
The univariate and multiple Cox regression analyses for the influence of age, gender, BM involvement, histoarchitectural pattern, stage, treatment, and subdiaphragmatic involvement on overall survival (OS) and progression-free survivals (PFS) are presented in Tables 6 and 7. The univariate analysis for overall survival time revealed that age, gender, BM involvement, histoarchitectural pattern, treatment, and subdiaphragmatic involvement are not significant risk factors for death at the level of 0.1 (all p > 0.1). Tumors with higher stages (III and IV) had lower survival rates than others (HR = 11.17, p = 0.038 for univariate and HR = 9.79, p = 0.05 for multiple Cox regression analysis) (Table 6, Fig. 4). After entering multiple Cox regression for adjustments histoarchitectural pattern showed no significant correlation with overall survival (Table 6, Fig. 5).
After adjustment for other variables, age (HR = 0.95, p = 0.04) and stage (HR = 14.08, p = 0.03) showed a significant correlation with PFS (Table 7). No significant correlation was found between histoarchitectural pattern and PFS (Table 7, Fig. 5).
The relationship between stage, subdiaphragmatic, and BM involvement with outcome is shown in Table 8. There are significant associations between disease stage, subdiaphragmatic, and BM involvement with outcome variables.
Discussion
Among the 1168 lymphoma cases involved in the current study, 32.7% (n = 382) of them were Hodgkin lymphomas. NLPHL accounted for 19.1% of the Hodgkin lymphomas. NLPHL is reported to account for 3–8% of HLs in Western countries [1,2,3, 11]. Its incidence is even lower in Asian countries [12, 13]. In a study reported in 2014 from our center, 9% of HLs were of NLPHL type [14]. Mozaheb et al. studied 391 lymphoma cases in Mashhad, Iran, and reported that 6.3% of their HLs were NLPHL [15]. In another study from Iran conducted by Shamloo et al. on 513 head and neck lymphoma cases, 200 HLs were identified, 24 (12%) of which were of the NLPHL type [16]. The higher incidence of NLPHL in the current study compared with studies from other countries as well as previous reports from Iran can be explained by various reasons. Recent publication of more precise diagnostic criteria for this entity may have led to better identification of this subtype, which may have caused its relative increased frequency. All the previously mentioned studies from Iran were published at least 3 to 4 years ago, and at that time NLPHL may have been under-diagnosed. It should be noted that in the most recent studies, NLPHL accounted for 12% of HLs which is similar to the current study [16]. Nevertheless, a recent increase in this lymphoma type cannot be excluded. Further studies are needed to confirm these results.
NLPHL mostly affects men in their 4th decade of life [3]. About 69.9% of patients in the current study were males, which is in line with other studies. In a study on 471 NLPHL cases, 75.8% of patients were males [17]. Similar results were reported by Molin et al. [18]. In another study reported by Eladl et al. from Japan, 64% of their NLPHL cases were males [12]. The median age of patients in the present study was 34 years (mean: 36.33 ± 14.5). Similar results have been reported by other researchers, and the reported median ages range between 32 and 56 years [12, 17, 19,20,21,22]. One study reported a significantly older age in affected females compared with males (59 vs. 44, p = 0.39), but others (including the current one) did not find such differences [18].
Regarding the histoarchitectural patterns, 48.5% of patients in this study showed a typical growth pattern, and the others were included in the variant group. Types A, C, and E of Fan’s classification were the most prevalent types, respectively. The rate of typical morphology varies in different studies ranging between 47 and 78% [7, 8, 10, 23]. Some studies have reported a higher rate of typical morphology than the current results [8, 23]. Hartmann et al. studied 423 NLPHL cases and reported that 72% of their patients showed a typical morphological pattern [7]. Another study by Agbay et al. reported that 47% of their NLPHL cases showed the classic pattern, and the others had a variant morphology or a mixture of typical and variant morphology [10]. In a study by Hartmann et al., which considered 33 cases treated within the German Hodgkin Study Group (GHSG) and 41 cases treated outside the GHSG, the typical morphology was identified in 64% of cases inside the GHSG and 44% of those out of it [19]. The authors declared that because of the more complicated diagnosis, these patients had not been involved in the GHSG study [19]. To determine the exact rate of typical and variant morphologies in NLPHL, more studies on larger sample sizes are needed. In addition, as the patients with more difficulties in diagnosis do not usually enter clinical trials, studies that include all diagnosed cases are preferred rather than ones including a selected number of cases.
The current study found a significant association between variant morphology and BM involvement. All patients with BM involvement showed the variant morphology. No significant association was found between histoarchitectural patterns and OS, PFS, or patient outcome. Similarly, in a study by Panjwani et al., all cases with BM involvement showed variant morphology [9]. In line with the current study, Hartmann et al. found a significant association between variant morphology and advanced disease. They also reported a significant association between variant morphology and a higher relapse rate and introduced variant morphology as an independent prognostic factor [7]. Another study by Agbay et al. found that BM involvement by lymphoma in NLPHL patients is more common in variant morphology (p = 0.02), which is similar to the current results [10]. Hartmann et al. found that presentation in an advanced stage is more common in patients with variant morphology [19]. In addition, they found that time to relapse correlates with histoarchitectural growth patterns (5.2 vs. 2.8 for typical and variant morphologies, respectively) [19]. Other studies on childhood NLPHL have also reported lower rates of complete response, higher rates of relapse, higher rates of unfavorable presentation, and lower EFS in variant morphology compared with typical morphology [23, 24]. The absence of a significant association between survival and histoarchitectural patterns in the current study may be related to the limited sample size as well as the short follow-up period (median follow-up time = 25 months). Furthermore, a limitation of the current study is that the patients did not receive uniform treatment and this may have influenced the results.
Several factors have been reported to affect the prognosis in NLPHL patients. In the current study, it was found that adverse outcome was associated with higher stages, BM involvement, and subdiaphragmatic disease involvement. In addition, patients with higher stage tumor (III and IV) showed lower OS and PFS rates. Eichenauer et al. studied 471 NLPHL cases and reported that PFS and OS were significantly related to BM and liver involvement. They also showed that OS was lower in advanced stage patients [17]. In line with the current results, Agbay et al. also found that disease progression and relapse were more frequent in patients with BM involvement [10]. Furthermore, the rate of BM involvement in the current study was 11% which is somewhat higher than reported elsewhere [9, 10]. It may be explained by the influence of a higher proportion of variant morphology in this study. In addition, in 3 (4.1%) cases in this study, the primary site of disease presentation was BM. To the best of our knowledge, such presentation has not been reported by others.
In conclusion, to the best of our knowledge, this is the first report from Iran on the histoarchitectural and clinical aspects of NLPHL. Higher frequencies of variant morphology as well as BM involvement were found compared with most other studies. The histoarchitectural patterns were associated with BM involvement but not with OS or PFS. Stage, BM involvement, and subdiaphragmatic involvement were significantly associated with outcome. Patients with higher stage tumors had lower OS and PFS rates.
Data availability
The datasets generated during the study are available in IBM SPSS format from the corresponding author on reasonable request.
References
Bazzeh F, Rihani R, Howard S, Sultan I (2010) Comparing adult and pediatric Hodgkin lymphoma in the surveillance, epidemiology and end results program, 1988–2005: an analysis of 21 734 cases. Leuk Lymphoma 51:2198–2207
Thomas R, Re D, Zander T, Wolf J, Diehl V (2002) Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol 13:147–152
Hartmann S, Eichenauer DA (2020) Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology 52:142–153
Anagnostopoulos I, Hansmann M-L, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken J, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H (2000) European task force on lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96:1889–1899
Stein H, Swerdlow SH, Gascoyne RD, Poppema S, Jaffe ES, Pileri SA (2017) Nodular lymphocyte predominant Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds) WHO classification of Tumours of Haematopoietic and lymphoid tissues, revised, 4th edn. IARC, Lyon, pp 431–434
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA (2003) Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 27:1346–1356
Hartmann S, Eichenauer DA, Plütschow A, Mottok A, Bob R, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller AC, Ott G, Möller P, Rosenwald A, Stein H, Hansmann ML, Engert A, Klapper W (2013) The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study group (GHSG). Blood 122:4246–4252
Shankar AG, Kirkwood AA, Hall GW, Hayward J, O'Hare P, Ramsay AD (2015) Childhood and adolescent nodular lymphocyte predominant Hodgkin lymphoma-a review of clinical outcome based on the histological variants. Br J Haematol 171:254–262
Panjwani P, Epari S, Sengar M, Laskar S, Menon H, Shet T (2015) Bone marrow involvement in nodular lymphocyte predominant Hodgkin lymphoma occurs in tumors with a variant pattern. Leuk lymphoma 56:236–238
Agbay RLMC, Loghavi S, Zuo Z, Fayad L, Dabaja B, Medeiros LJ, Khoury JD (2018) Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 42:492–499
Colby TV, Hoppe RT, Warnke RA (1982) Hodgkin’s disease: a clinicopathologic study of 659 cases. Cancer 49:1848–1858
Eladl AE, Satou A, Elsayed AA, Suzuki Y, Shimizu-Kohno K, Kato S, Tomita A, Kinoshita T, Nakamura S, Asano N (2015) Nodular lymphocyte predominant Hodgkin lymphoma: clinicopathological study of 25 cases from Japan with a reappraisal of tissue associated macrophages. Pathol Int 65:652–660
Yang Q-P, Zhang W-Y, Yu J-B, Zhao S, Xu H, Wang W-Y, Bi CF, Zuo Z, Wang XQ, Huang J, Dai L, Liu WP (2011) Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol 6:77
Monabati A, Safaei A, Noori S, Mokhtari M, Vahedi A (2016) Subtype distribution of lymphomas in south of Iran, analysis of 1085 cases based on World Health Organization classification. Ann Hematol 95:613–618
Mozaheb Z, Aledavood A, Farzad F (2011) Distributions of major sub-types of lymphoid malignancies among adults in Mashhad, Iran. Cancer Epidemiol 35:26–29
Shamloo N, Ghannadan A, Jafari M, Ahmadi S, Mortazavi H, Baharvand M (2017) Head and neck lymphoma in an Iranian population. Iran J Otorhinolaryngol 29:261
Eichenauer DA, Plütschow A, Fuchs M, Sasse S, Baues C, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A (2020) Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group. J Clin Oncol 38:698–705
Molin D, Linderoth J, Wahlin BE (2017) Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. Br J Haematol 177:449–456
Hartmann S, Plütschow A, Mottok A, Bernd HW, Feller AC, Ott G, Cogliatti S, Fend F, Quintanilla-Martinez L, Stein H, Klapper W, Möller P, Rosenwald A, Engert A, Hansmann ML, Eichenauer DA (2019) The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. Am J Hematol 94:1208–1213
Shivarov V, Ivanova M (2018) Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. Br J Haematol 182:727–730
Posthuma HL, Zijlstra JM, Visser O, Lugtenburg PJ, Kersten MJ, Dinmohamed AG (2020) Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993–2016. Br J Haematol 189:117–121
Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ (2019) Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood 133:2121–2129
Prasad M, Narula G, Chinnaswamy G, Arora B, Shet T, Panjwani P, Sengar M, Laskar S, Khanna N, Banavali S (2018) Unfavorable presentation but comparable outcome: presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India. Pediatr Blood Cancer 65:e27288
Untanu RV, Back J, Appel B, Pei Q, Chen L, Buxton A, Hodgson DC, Ehrlich PF, Constine LS, Schwartz CL, Hutchison RE (2018) Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 65:e26753
Acknowledgments
We gratefully acknowledge our colleagues from the laboratory of Shahid Faghihi Hospital as well as other hospitals affiliated with Shiraz University of Medical Sciences, Shiraz, Iran.
Funding
The study was supported by a grant from Shiraz University of Medical Sciences, Shiraz, Iran.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study design. Data collection and analysis were performed by Ahmad Monabati, Akbar Safaei, Maral Mokhtari, Pardis Nematollahi, and Samaneh Boroumand-Noughabi. Statistical analysis was done by Marjan Faghih. The first draft of the manuscript was written by Samaneh Boroumand-Noughabi, and all authors commented on the previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Ethical approval
This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the Research Ethics Committee in Shiraz University of Medical Sciences (IR.SUMS.MED.REC.1398.466).
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Monabati, A., Safaei, A., Mokhtari, M. et al. Histopathological and clinical features of nodular lymphocyte-predominant Hodgkin lymphoma and their impact on prognosis: first report from Iran. J Hematopathol 13, 143–152 (2020). https://doi.org/10.1007/s12308-020-00410-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12308-020-00410-y